Innovative Solutions for Fast-Tracking Drugs for Rare Diseases
This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…
Certara2019年8月10日
Evidence and Access Overview
Discover Certara’s holistic approach to market access.
Certara2019年5月21日
Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement
This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…
Certara2019年5月13日
Trends for Market Access, HEOR, and Real World Evidence
This blog reviews trends for using health economics and outcomes research and real-world evidence to…
Certara2019年5月10日
Real World Evidence Marches Forward in Drug Development
The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…
Certara2019年3月20日
Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond
Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…
Certara2018年6月2日
Drug Asset Evaluation: Increasing “Probability of Success” of a Deal
Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…
Certara2017年8月24日
Model-based Meta-analysis: An Innovative Methodology Comes of Age
MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions.…
Certara2016年7月14日
Short-term Efficacy Reliably Predicts Long-term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-based Meta-analysis
The objective of this study was to assess the relationship between short-term and long-term treatment…
Certara2016年7月1日
